Maximus, Inc. $MMS Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its stake in Maximus, Inc. (NYSE:MMS) by 19.8% during the 3rd quarter, Holdings Channel reports. The fund owned 200,331 shares of the health services provider’s stock after acquiring an additional 33,136 shares during the period. JPMorgan Chase & Co.’s holdings in Maximus were worth $18,304,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in MMS. Norges Bank acquired a new position in Maximus in the 2nd quarter valued at about $47,886,000. Boston Partners boosted its stake in shares of Maximus by 113.6% during the 2nd quarter. Boston Partners now owns 657,247 shares of the health services provider’s stock worth $46,435,000 after purchasing an additional 349,529 shares during the last quarter. River Road Asset Management LLC purchased a new stake in shares of Maximus during the second quarter worth about $18,073,000. Stephens Investment Management Group LLC grew its holdings in shares of Maximus by 49.0% during the third quarter. Stephens Investment Management Group LLC now owns 720,943 shares of the health services provider’s stock worth $65,873,000 after buying an additional 237,097 shares in the last quarter. Finally, Voya Investment Management LLC raised its position in shares of Maximus by 1,380.3% in the third quarter. Voya Investment Management LLC now owns 228,488 shares of the health services provider’s stock valued at $20,877,000 after buying an additional 213,053 shares during the last quarter. Institutional investors and hedge funds own 97.21% of the company’s stock.

Maximus Trading Up 1.0%

MMS stock opened at $67.82 on Thursday. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.88. The company has a market cap of $3.70 billion, a price-to-earnings ratio of 10.32 and a beta of 0.59. The business has a fifty day simple moving average of $80.54 and a 200-day simple moving average of $84.62. Maximus, Inc. has a 52 week low of $64.68 and a 52 week high of $100.00.

Maximus (NYSE:MMS) last issued its earnings results on Thursday, February 5th. The health services provider reported $1.85 earnings per share for the quarter, beating analysts’ consensus estimates of $1.84 by $0.01. Maximus had a return on equity of 25.30% and a net margin of 6.92%.The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.37 billion. During the same quarter last year, the firm earned $1.61 earnings per share. The firm’s revenue for the quarter was down 4.1% compared to the same quarter last year. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. On average, equities research analysts expect that Maximus, Inc. will post 6.15 EPS for the current year.

Maximus Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were paid a $0.33 dividend. The ex-dividend date of this dividend was Friday, February 13th. This represents a $1.32 annualized dividend and a dividend yield of 1.9%. This is an increase from Maximus’s previous quarterly dividend of $0.30. Maximus’s dividend payout ratio is presently 20.09%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Zacks Research upgraded shares of Maximus from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 30th. Weiss Ratings downgraded Maximus from a “buy (b)” rating to a “hold (c+)” rating in a report on Tuesday, February 24th. Finally, Wall Street Zen lowered Maximus from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy”.

Insider Transactions at Maximus

In related news, Director Jan Madsen sold 742 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $72.25, for a total value of $53,609.50. Following the transaction, the director owned 20,795 shares in the company, valued at approximately $1,502,438.75. This trade represents a 3.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Bruce Caswell purchased 3,175 shares of Maximus stock in a transaction on Tuesday, February 10th. The shares were acquired at an average cost of $78.45 per share, for a total transaction of $249,078.75. Following the completion of the transaction, the chief executive officer owned 328,013 shares of the company’s stock, valued at $25,732,619.85. This represents a 0.98% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 1.80% of the company’s stock.

Maximus Company Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.